BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Areberg J, Petersen KB, Chen G, Naik H. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol 2014;115:552-9. [PMID: 24766668 DOI: 10.1111/bcpt.12256] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Gu E, Huang C, Liang B, Yuan L, Lan T, Hu G, Zhou H. An UPLC–MS/MS method for the quantitation of vortioxetine in rat plasma: Application to a pharmacokinetic study. Journal of Chromatography B 2015;997:70-4. [DOI: 10.1016/j.jchromb.2015.05.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
2 Naik H, Chan S, Vakilynejad M, Chen G, Loft H, Mahableshwarkar AR, Areberg J. A Population Pharmacokinetic–Pharmacodynamic Meta‐Analysis of Vortioxetine in Patients with Major Depressive Disorder. Basic Clin Pharmacol Toxicol 2016;118:344-55. [DOI: 10.1111/bcpt.12513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
3 Yi Y, Ren G, Zheng M, Zhao D, Li N, Chen X, Lu Y. Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. Journal of Chromatography B 2020;1138:121955. [DOI: 10.1016/j.jchromb.2019.121955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Chen G, Nomikos GG, Affinito J, Jacobson W, Zhao Z, Wang S, Xie J. Effects of Intrinsic Factors on the Clinical Pharmacokinetics of Vortioxetine. Clinical Pharmacology in Drug Development 2018;7:880-8. [DOI: 10.1002/cpdd.577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Frederiksen T, Areberg J, Schmidt E, Bjerregaard Stage T, Brøsen K. Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine. Clin Pharmacol Ther 2021;109:150-9. [PMID: 32599653 DOI: 10.1002/cpt.1972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
6 Matsuno K, Nakamura K, Aritomi Y, Nishimura A. Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single- and Multiple-Dose Administration in Healthy Japanese Adults. Clin Pharmacol Drug Dev 2018;7:319-31. [PMID: 28941196 DOI: 10.1002/cpdd.381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Salagre E, Grande I, Solé B, Sanchez-moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Revista de Psiquiatría y Salud Mental (English Edition) 2018;11:48-59. [DOI: 10.1016/j.rpsmen.2018.02.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Findling RL, Robb AS, DelBello M, Huss M, McNamara N, Sarkis E, Scheffer R, Poulsen LH, Chen G, Lemming OM, Areberg J, Auby P. Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients. J Child Adolesc Psychopharmacol 2017;27:526-34. [PMID: 28333546 DOI: 10.1089/cap.2016.0155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
9 Rancans E, Zambori J, Dalsgaard M, Baayen C, Areberg J, Ettrup A, Florea I. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study. Int Clin Psychopharmacol 2020;35:305-12. [PMID: 32784346 DOI: 10.1097/YIC.0000000000000326] [Reference Citation Analysis]
10 Shalimova A, Babasieva V, Chubarev VN, Tarasov VV, Schiöth HB, Mwinyi J. Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 2021;22:485-503. [PMID: 34018822 DOI: 10.2217/pgs-2020-0157] [Reference Citation Analysis]
11 Danielak D. Vortioxetine in management of major depressive disorder - a favorable alternative for elderly patients? Expert Opin Pharmacother 2021;22:1167-77. [PMID: 33650935 DOI: 10.1080/14656566.2021.1880567] [Reference Citation Analysis]
12 Greenblatt DJ, Harmatz JS, Chow CR. Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. J Clin Psychopharmacol 2018;38:172-9. [DOI: 10.1097/jcp.0000000000000861] [Cited by in Crossref: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Frederiksen T, Smith RL, Wollmann BM, Areberg J, Molden E. Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. Clin Pharmacokinet 2021. [PMID: 34121163 DOI: 10.1007/s40262-021-01029-7] [Reference Citation Analysis]
14 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 13.3] [Reference Citation Analysis]
15 Ketola RA, Ojanperä I. Summary statistics for drug concentrations in post‐mortem femoral blood representing all causes of death. Drug Test Anal 2019;11:1326-37. [DOI: 10.1002/dta.2655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
16 Miao J, Wang G, Hou J, Areberg J, Zhao Y, Højer AM, Ettrup A. Pharmacokinetics and Safety of Vortioxetine in the Chinese Population. Adv Ther 2019;36:3134-46. [PMID: 31552551 DOI: 10.1007/s12325-019-01092-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Salagre E, Grande I, Solé B, Sanchez-Moreno J, Vieta E. Vortioxetine: A new alternative for the treatment of major depressive disorder. Rev Psiquiatr Salud Ment (Engl Ed) 2018;11:48-59. [PMID: 28800937 DOI: 10.1016/j.rpsm.2017.06.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
18 Darney K, Lautz LS, Béchaux C, Wiecek W, Testai E, Amzal B, Dorne JLCM. Human variability in polymorphic CYP2D6 metabolism: Implications for the risk assessment of chemicals in food and emerging designer drugs. Environ Int 2021;156:106760. [PMID: 34256299 DOI: 10.1016/j.envint.2021.106760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Fourrier C, Sampson E, Mills NT, Baune BT. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials 2018;19:447. [PMID: 30126458 DOI: 10.1186/s13063-018-2829-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
20 Nissen TD, Laursen B, Viardot G, l'Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM. Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings – A Randomized, Crossover Trial in Healthy Males. Neuroscience 2020;424:172-81. [DOI: 10.1016/j.neuroscience.2019.09.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2019;34:153-60. [PMID: 31094901 DOI: 10.1097/YIC.0000000000000271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert Opinion on Drug Metabolism & Toxicology 2019;15:831-47. [DOI: 10.1080/17425255.2019.1669560] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Hoffelt C, Gross T. A review of significant pharmacokinetic drug interactions with antidepressants and their management. Ment Health Clin 2016;6:35-41. [PMID: 29955445 DOI: 10.9740/mhc.2016.01.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
25 Larsen KG, Areberg J, Åström DO. Are self-reported and self-monitored adherence good proxies for reaching relevant plasma concentrations?: Experiences from a study of anti-depressants in healthy volunteers. Clin Trials 2021;18:505-10. [PMID: 33938259 DOI: 10.1177/17407745211012683] [Reference Citation Analysis]